B. Riley Increases Lantheus (NASDAQ:LNTH) Price Target to $99.00

Lantheus (NASDAQ:LNTH) had its price target boosted by analysts at B. Riley from $95.00 to $99.00 in a research report issued on Thursday, Benzinga reports. The firm presently has a “buy” rating on the medical equipment provider’s stock. B. Riley’s price objective indicates a potential upside of 55.15% from the company’s previous close.

Several other research analysts also recently commented on LNTH. JMP Securities reiterated a “market outperform” rating and issued a $100.00 target price on shares of Lantheus in a report on Friday, February 23rd. Truist Financial restated a “buy” rating and issued a $82.00 price target (up from $80.00) on shares of Lantheus in a research report on Monday, February 26th. Finally, StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $104.71.

Lantheus Stock Performance

Shares of LNTH opened at $63.81 on Thursday. The company has a market capitalization of $4.37 billion, a PE ratio of 13.75 and a beta of 0.53. Lantheus has a one year low of $50.20 and a one year high of $100.85. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.80 and a quick ratio of 5.45. The company’s fifty day moving average price is $60.81 and its 200 day moving average price is $62.97.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, topping the consensus estimate of $1.33 by $0.26. The firm had revenue of $354.00 million for the quarter, compared to the consensus estimate of $350.44 million. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. As a group, analysts expect that Lantheus will post 5.72 earnings per share for the current year.

Insider Activity

In other news, Director Mary Anne Heino sold 93,863 shares of Lantheus stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the sale, the director now directly owns 251,643 shares in the company, valued at approximately $16,434,804.33. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The shares were acquired at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the transaction, the insider now owns 116,773,394 shares in the company, valued at $110,934,724.30. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mary Anne Heino sold 93,863 shares of Lantheus stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the sale, the director now owns 251,643 shares in the company, valued at $16,434,804.33. The disclosure for this sale can be found here. In the last three months, insiders have sold 94,545 shares of company stock worth $6,169,936. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Lantheus

Institutional investors have recently added to or reduced their stakes in the company. Tucker Asset Management LLC lifted its holdings in Lantheus by 239.0% during the 3rd quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 282 shares during the last quarter. Parkside Financial Bank & Trust lifted its holdings in Lantheus by 60.2% during the 2nd quarter. Parkside Financial Bank & Trust now owns 426 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 160 shares during the last quarter. First Horizon Advisors Inc. lifted its holdings in Lantheus by 97.0% during the 3rd quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 225 shares during the last quarter. Principal Securities Inc. bought a new position in Lantheus during the 4th quarter valued at about $28,000. Finally, West Tower Group LLC lifted its holdings in Lantheus by 534.1% during the 4th quarter. West Tower Group LLC now owns 520 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 438 shares during the last quarter. 99.06% of the stock is owned by institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.